Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Videos|November 26, 2013
The Identification and Treatment of Ovarian Cancer
Author(s)Franco M. Muggia, MD
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the identification and treatment of ovarian cancer.
Advertisement
Clinical Pearls
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the identification and treatment of ovarian cancer.
- There is no way of identifying ovarian cancer early
- Often times, ovarian cancer starts in the fallopian tubes, which affects the biology of the cancer
- Research has focused on the BRCA gene in ovarian cancer because it is a clearly-identified target
Advertisement
Related to this article
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Dr Wang Highlights ESMO Lung Cancer Data Making an Impact
5